Podcast Center
Video Center
Webcasts
Resource Center
Events
February 08, 2017 at 08:34 AM
(Bloomberg) — President Donald Trump supports Medicare drug price negotiations, his spokesman said Tuesday, remarks that sent pharmaceutical stocks swinging again as investors tried to assess whether drugmakers will be forced into bidding wars for government business.
“He’s for it, yes,” White House spokesman Sean Spicer said at a press briefing in response to a question asking to clarify Trump’s position on the matter.
Trump has given conflicting signals in the past weeks on whether he would let the government intervene directly in drug prices to reduce health care costs. The Medicare program for the elderly is the biggest purchaser of health services in the country, and bidding for its business could have a major impact on Big Pharma’s profits. Unlike most countries in the world, the U.S. doesn’t directly regulate medicine prices, and drugmakers have strongly resisted it.
Related: Trump volatility index has taken pharma companies on a wild ride
“The easier way to look at this is to look at what other countries have done: Negotiating costs to keep those down,” Spicer said at the briefing. The rising costs of health care and prescription drugs are a “huge burden” on seniors, he said.
The Nasdaq Biotechnology Index fell as much as 0.8 percent in the moments after Spicer’s remarks. The gauge pared the decline and was down 0.4 percent at the New York close. The Standard & Poor’s 500 Health Care Sector Index was little changed.
Surprising comments
Spicer’s comments took investors by surprise because Trump appeared to have backed down from the idea last week after a meeting at the White House with top pharmaceutical CEOs. Although the president said at the time that competition was key to lowering drug prices, which he called “astronomical,” he also added that he was against price fixing.
“My new thing is going to be pharma, because we pay too much,” Trump said in a Fox News interview that aired Tuesday night. “We are the largest drug purchaser in the world, and they don’t negotiate.”
